Novartis acquires Regulus Therapeutics for $1.7 billion, focusing on developing potential medicine

From Yahoo Finance: 2025-06-28 12:39:00

Novartis AG (NYSE:NVS) has completed the acquisition of Regulus Therapeutics for $1.7 billion, making Regulus a fully owned subsidiary of Novartis. The acquisition is a crucial step in advancing the development of a potential medicine for autosomal dominant polycystic kidney disease. Novartis is a global healthcare company focused on discovering and developing innovative medicines to address medical challenges like cancer and rare genetic disorders. Operating in over 100 countries, the US accounts for about one-third of Novartis’s revenue. While Novartis is seen as a solid investment, some believe that certain AI stocks offer greater potential.



Read more at Yahoo Finance: Novartis (NVS) Acquires Regulus Therapeutics for $1.7 Billion